Does Rallies show 13F holders for VERA?

Yes. Rallies tracks hedge fund and 13F ownership data for VERA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is VERA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for VERA. It does not provide personalized investment advice.

VERA (Vera Therapeutics, Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Vera Therapeutics, Inc. Class A Common Stock (VERA) is a publicly traded Healthcare sector company. As of May 21, 2026, VERA trades at $34.67 with a market cap of $2.47B and a P/E ratio of -7.31. VERA moved +4.15% today. Year to date, VERA is -26.45%; over the trailing twelve months it is +62.99%. Its 52-week range spans $18.53 to $56.05. Analyst consensus is strong buy with an average price target of $77.67. Rallies surfaces VERA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns VERA stock?

Hedge funds tracked by Rallies that own VERA include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vera Therapeutics, Inc. Class A Common Stock.

VERA Key Metrics

Key financial metrics for VERA
Metric	Value
Price	$34.67
Market Cap	$2.47B
P/E Ratio	-7.31
EPS	$-4.66
Dividend Yield	0.00%
52-Week High	$56.05
52-Week Low	$18.53
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-299.62M
Gross Margin	0.00%

Top Hedge Funds Holding VERA

Orbimed Advisors holds 369.60K shares of VERA, changed +4.55% as of Mar 31, 2026.
Centerbook Partners holds 97.00K shares of VERA, changed +520.26% as of Mar 31, 2026.

Latest VERA News

Vera Therapeutics Grants 40,250 Options and 20,125 RSUs at $35.51 Exercise Price — May 8, 2026
Vera Therapeutics Wins FDA Priority Review with July 7 PDUFA; Q1 Loss $121M — May 7, 2026
Vera Therapeutics grants 258,200 options, 131,925 RSUs at $40.33 to 89 hires — Apr 10, 2026
Vera Therapeutics Names Jane Wright-Mitchell as CLO Ahead of Atacicept Launch — Mar 25, 2026
Vera Therapeutics Grants 46,000 Options at $39.30 Strike to Six New Hires — Mar 6, 2026

Recent VERA Insider Trades

Fordyce Marshall sold 14.22K (~$520.98K) on May 12, 2026.
Fordyce Marshall sold 4.28K (~$158.77K) on May 12, 2026.
Fordyce Marshall sold 14.13K (~$616.99K) on Apr 14, 2026.

VERA Analyst Consensus

9 analysts cover VERA: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $77.67.

Common questions about VERA

Who owns VERA stock?: Hedge funds tracked by Rallies that own VERA include Orbimed Advisors and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Vera Therapeutics, Inc. Class A Common Stock.
Does Rallies show 13F holders for VERA?: Yes. Rallies tracks hedge fund and 13F ownership data for VERA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is VERA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for VERA. It does not provide personalized investment advice.